- Home
- API vs RIGL Comparison
API vs RIGL Comparison
Compare API & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- RIGL
- Stock Information
- Founded
- API 2013
- RIGL 1996
- Country
- API United States
- RIGL United States
- Employees
- API N/A
- RIGL N/A
- Industry
- API Computer Software: Prepackaged Software
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- API Technology
- RIGL Health Care
- Exchange
- API Nasdaq
- RIGL Nasdaq
- Market Cap
- API 343.2M
- RIGL 335.5M
- IPO Year
- API 2020
- RIGL 2000
- Fundamental
- Price
- API $3.45
- RIGL $38.85
- Analyst Decision
- API Strong Buy
- RIGL Buy
- Analyst Count
- API 1
- RIGL 5
- Target Price
- API $6.00
- RIGL $38.20
- AVG Volume (30 Days)
- API 508.9K
- RIGL 995.6K
- Earning Date
- API 08-18-2025
- RIGL 08-05-2025
- Dividend Yield
- API N/A
- RIGL N/A
- EPS Growth
- API N/A
- RIGL N/A
- EPS
- API N/A
- RIGL 5.43
- Revenue
- API $133,554,000.00
- RIGL $267,921,000.00
- Revenue This Year
- API $7.20
- RIGL $59.93
- Revenue Next Year
- API $11.26
- RIGL N/A
- P/E Ratio
- API N/A
- RIGL $7.15
- Revenue Growth
- API N/A
- RIGL 105.62
- 52 Week Low
- API $1.78
- RIGL $12.66
- 52 Week High
- API $6.99
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- API 40.21
- RIGL 68.57
- Support Level
- API $3.48
- RIGL $39.00
- Resistance Level
- API $3.67
- RIGL $42.08
- Average True Range (ATR)
- API 0.19
- RIGL 2.32
- MACD
- API -0.02
- RIGL -0.37
- Stochastic Oscillator
- API 10.17
- RIGL 53.26
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.